Introduction

Haleon plc (LSE:HLN), a consumer-health company that demerged from GSK in 2022, is connected to the antiviral aciclovir (also spelled acyclovir) through Zovirax, a well-known over-the-counter cold-sore brand. Zovirax cold-sore products contain aciclovir and are used to treat cold sores caused by the herpes simplex virus. This is a verified, direct consumer-health relationship: Zovirax is one of the brands in Haleon’s portfolio.

This article explains what aciclovir is in this consumer context, how Haleon is connected to it, and — importantly — how the consumer Zovirax range differs from prescription-only aciclovir medicines supplied by other companies. It distinguishes clinical facts from commercial analysis and does not provide medical or financial advice. It also makes clear what an MHRA active-substance listing does and does not establish.

What is the medicine?

Aciclovir is an antiviral medicine that is active against herpes viruses, including the herpes simplex virus that causes cold sores. In its consumer form, sold under the Zovirax brand, aciclovir is used as a topical cream to treat cold sores on the lips and around the mouth.

It is important to note that aciclovir exists in many formulations. The Zovirax consumer cold-sore products are over-the-counter items intended for self-treatment of a common, self-limiting condition. Prescription-only aciclovir products — such as tablets, eye ointment and injectable forms used for more serious infections — are different medicines with different supply arrangements.

The MHRA index reflects this variety by listing aciclovir under multiple product files. That breadth is precisely why a substance listing cannot be read as a statement of ownership: the same active ingredient underpins consumer creams, pharmacy medicines and hospital treatments supplied by a range of different companies.

Which UK-listed company is connected to it?

Haleon plc, listed on the London Stock Exchange under the ticker HLN, markets the Zovirax consumer cold-sore range. Haleon is a dedicated consumer-health business that was created when it separated from GSK in 2022, taking a portfolio of well-established everyday-health brands with it.

The relationship here is specific: Haleon’s connection to aciclovir is through the Zovirax over-the-counter cold-sore products, not through the prescription aciclovir medicines that other companies supply. This distinction — between consumer-health brands and prescription medicines retained by or transferred from a former parent — is essential to understanding the exposure accurately.

What does the MHRA substance listing establish?

An MHRA index entry for aciclovir confirms only that regulatory or product files exist under that active substance. It does not establish that any single company owns every product containing aciclovir.

Aciclovir is a long-established, off-patent medicine available from many manufacturers, including numerous generic suppliers, across both prescription and pharmacy or general-sale settings. The listing therefore does not, on its own, connect aciclovir to Haleon. This article’s statement of the relationship is based on Haleon’s brand portfolio and the Zovirax product information, not on the substance index alone.

What is the product approved to treat?

According to the approved product information for the consumer Zovirax cold-sore cream, aciclovir is used for the treatment of cold sores (herpes labialis) — the recurrent blisters around the lips and mouth caused by the herpes simplex virus. It is applied topically to the affected area as directed on the label.

This is a consumer indication for a common, generally self-limiting condition, and it is distinct from the broader indications of prescription aciclovir products used for other, sometimes serious, herpes infections. Readers should follow the specific label and patient information leaflet for the product they are using.

Consumer cold-sore treatments are designed for straightforward self-care, and their labelling includes guidance on when to seek professional advice — for example if cold sores are frequent, severe, unusually persistent, or occur in people with weakened immune systems. This built-in signposting is part of what distinguishes a general-sale or pharmacy medicine from a prescription-only one.

How does the medicine work?

Aciclovir works by interfering with the herpes virus’s ability to replicate. Once inside infected cells, it is converted into an active form that blocks the viral enzyme needed to copy the virus’s genetic material, helping to limit the spread of the infection.

In cold-sore treatment, applying aciclovir cream early — typically when the first tingling signs appear — is intended to help manage an outbreak. Aciclovir does not eliminate the virus from the body, which remains dormant and can reactivate. Individual results vary, and persistent or severe symptoms should be discussed with a pharmacist or doctor.

What are the key regulatory and brand milestones?

Aciclovir was a landmark antiviral first developed in the late twentieth century and has long since become a widely available, off-patent medicine. The Zovirax brand became a well-known consumer name for cold-sore treatment over many years.

A key corporate milestone relevant to investors is Haleon’s creation as a standalone, listed consumer-health company following its separation from GSK in 2022. Zovirax was among the consumer brands that became part of Haleon. The active substance itself is mature; the more relevant developments for Haleon concern brand management and portfolio strategy rather than new drug approvals.

Haleon’s primary listing is on the London Stock Exchange under the ticker HLN, and it is one of the larger listed consumer-health companies. For a business of this type, value is built through brands, distribution and category leadership over long periods, rather than through the kind of single-event regulatory catalysts that can move a prescription-pharmaceutical company’s shares.

How important is the product to the company’s portfolio?

Zovirax is one of many brands in Haleon’s diversified consumer-health portfolio, which spans categories such as oral health, pain relief, respiratory health, digestive health and skin or therapeutic care. No single small brand typically dominates such a portfolio.

Haleon generally reports performance by category and by so-called power brands rather than disclosing revenue for every individual product. Where Zovirax-specific revenue is not separately disclosed, this article does not estimate it. The reasonable interpretation is that Zovirax is a recognised brand contributing within a much larger, broadly based portfolio.

This portfolio breadth is a defining feature of the consumer-health model. Diversification across many everyday brands and geographies can make revenue relatively resilient, but it also means that no single small brand is likely to be individually material to group results. Zovirax should therefore be understood as a contributor to a category, not as a standalone financial lever.

What is the size and nature of the addressable market?

Cold sores are common, and the market for over-the-counter cold-sore treatments is a steady, consumer-driven segment. Demand tends to be recurring rather than one-off, because affected individuals may experience repeat outbreaks.

This market is shaped by consumer awareness, brand loyalty, pricing, retailer relationships and the availability of cheaper generic aciclovir and alternative products. As an everyday-health category, it is generally less exposed to the patent cliffs and reimbursement dynamics that affect prescription pharmaceuticals, but it is highly competitive.

Seasonality and lifestyle factors can also influence demand, since cold-sore outbreaks may be triggered by sunlight, stress or illness. For a consumer brand, marketing that connects with these everyday triggers, alongside reliable retail availability, tends to matter more than the kind of clinical differentiation that drives prescription-medicine sales.

What competing treatments are available?

The cold-sore category includes generic aciclovir creams, other antiviral creams such as penciclovir-based products, and non-antiviral options including cold-sore patches and soothing or barrier treatments. Own-label and store-brand products also compete directly on price.

Because aciclovir is off-patent, Zovirax competes not only with other brands but also with lower-cost generics containing the same active substance. Brand strength, consumer trust, packaging, and retail presence therefore matter a great deal in this segment. Consumers choose products based on preference and, where appropriate, pharmacist advice.

The rise of retailer own-label products is a notable dynamic across consumer health. When a trusted active substance is available cheaply under a supermarket or pharmacy label, established brands must justify a price premium through recognition, formulation or convenience. This competitive pressure is a structural feature of the category rather than a temporary challenge.

What could support future demand?

Factors that could support Zovirax demand include sustained brand recognition, effective marketing, product-range innovation such as patches or convenient formats, and continued consumer preference for a trusted name over generics.

Broader trends toward self-care and over-the-counter treatment of minor conditions may also support the category. However, demand is not guaranteed: it depends on competition from generics and alternatives, pricing, retailer dynamics and consumer behaviour. Any contribution to Haleon will reflect these everyday-market factors rather than regulatory approvals.

What are the principal clinical, regulatory and commercial risks?

Clinically, aciclovir cold-sore cream is generally well tolerated when used as directed, but, like all medicines, it can have side effects and is not suitable for every situation; persistent, severe or unusual symptoms warrant professional advice. Regulatory oversight of consumer medicines and their advertising continues to apply.

Commercially, the main risks include intense competition from generics and alternative products, private-label pressure, pricing sensitivity, and the reality that a single consumer brand is a small part of Haleon’s overall performance. Reputation and brand management are important in the consumer-health sector.

What should investors monitor next?

Investors interested in this specific link may wish to monitor Haleon’s category-level disclosures (for example within therapeutics, skin health or oral health), any commentary on power brands, and broader consumer-health trends such as self-care adoption and private-label competition.

They may also track Haleon’s overall organic revenue growth, margins and portfolio decisions. Zovirax itself is unlikely to be a standalone driver of group results, so the more informative signals are category performance and the health of the wider portfolio.

Portfolio management is another area to watch. Consumer-health companies periodically review their brand line-ups, investing behind priority names and sometimes divesting smaller ones. How Haleon chooses to support or reshape brands like Zovirax over time can offer clues about where management sees the best long-term returns.

Balanced conclusion

Haleon plc (LSE:HLN) is connected to aciclovir through Zovirax, a verified over-the-counter cold-sore brand within its consumer-health portfolio. The essential nuance is that this is a consumer product distinct from prescription aciclovir medicines supplied by others, and that an MHRA active-substance listing does not by itself connect aciclovir to Haleon. Zovirax is a recognised brand, but it operates in a competitive, off-patent category and is one of many products in a diversified group.

For a general investor audience, the sensible view is that Zovirax is a familiar consumer brand contributing modestly within a much larger portfolio, rather than a significant standalone value driver. The verified takeaway is simply that the Haleon–aciclovir link is real and runs specifically through the Zovirax cold-sore range, with prescription aciclovir products remaining outside Haleon’s consumer business. Anyone considering action based on this information should consult the primary sources cited and, where appropriate, professional advice.